metricas
covid
Buscar en
Cirugía Española
Toda la web
Inicio Cirugía Española Valoración inmunohistoquímica de la expresión de c-erb B2 como variable indep...
Información de la revista
Vol. 70. Núm. 3.
Páginas 142-146 (septiembre 2001)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 70. Núm. 3.
Páginas 142-146 (septiembre 2001)
Acceso a texto completo
Valoración inmunohistoquímica de la expresión de c-erb B2 como variable independiente en el carcinoma mamario T2N1 patológico
Immunohistochemical evaluation of c-erb B2 expression as an independent variable in T2N1 breast carcinoma
Visitas
11773
F. Vicente García1,*, B. Larrinaga**, M.C. Miranda Murua*, P. Soriano Gil Albarellos**, A. Calvo Benito*, J.M. Lera Tricas*
* Servicio de Cirugía General y digestiva
** Servicio de Anatomía Patológica. Hospital de Navarra. Pamplona
Este artículo ha recibido
Información del artículo
Resumen
Introducción

La incidencia de carcinoma mamario oscila entre 11 y 80 casos por 100.000 mujeres/año. El desarrollo de técnicas de inmunohistoquímica, para la determinación de marcadores tumorales ha posibilitado la realización de trabajos retrospectivos que nos permitan valorar su utilidad como factores pronósticos. Diversos trabajos relacionan la sobreexpresión de c-erb B2 con factores pronósticos. El objeto de nuestro estudio es determinar si la sobreexpresión de c-erb B2 es un factor pronóstico independiente en el grupo de pacientes seleccionado.

Pacientes y métodos

Se trata de 83 pacientes intervenidas entre 1980 y 1990 por carcinoma ductal infiltrante de mama, T2N1 patológico.

Hemos utilizando el kit Super Sensitive Immunodetection System de Biogenex, para la determinación de c-erb B2.

El análisis estadístico de los datos obtenidos se ha realizado mediante las pruebas de ?2 para variables cualitativas y la t de Student y análisis de la variancia para variables cuantitativas.

Resultados

El 35% de las pacientes mostró sobreexpresión de c-erb B2. El 48% de las pacientes prasentó progresión de la enfermedad. No hemos encontrado diferencias significativas al comparar sobreexpresión de c-erb B2 con ningún parámetro estudiado salvo una relación inversa, estadísticamente significativa, entre c-erb B2 y receptores estrogénicos (p = 0,0403).

Conclusiones

El c-erb B2 determinado mediante inmunohistoquímica no es un factor independiente de pronóstico en carcinomas ductales infiltrantes de mama T2N1.

Los receptores estrogénicos presentan una relación inversa con c-erb B2 con significación estadística.

Palabras clave:
Cáncer de mama
c-erb B2
Pronóstico
Inmunohistoquímica
Introduction

The incidence of breast carcinoma oscillates between 11 and 80 cases per 100,000 women/ year. Due to the development of immunohistochemical techniques for the determination of tumoral markers, retrospective studies can be performed to evaluate their utility as prognostic factors. Several studies have associated c-erb-B2 overexpression with prognostic factors. The aim of this study was to determine whether c-erb B2 overexpression is an independent prognostic factor in the group of patients selected.

Patients and methods

We studied a series of 83 women who underwent surgery for infiltrating T2 N1 ductal carcinoma of the breast between 1980 and 1990. The Biogenex super sensitive immunodetection system was used to determine c-erb B2. In the statistical analysis the Chi-squared test and Student‘s ttest were used to evaluate qualitative variables and analysis of variance was used to evaluate quantitative variables.

Results

Thirty-five percent of the patients showed overexpression of c-erb B2. Forty-eight percent of the patients showed disease progression. No significant differences were found in the comparison between cerb B2 overexpression and the other variables studied except an inverse, statistically significant relationship between c-erbB2 and estrogen receptors (p = 0.0403). Conclusions. Immunohistochemically-determined cerb B2 is not an independent prognostic factor in T2 N1 infiltrating ductal carcinoma of the breast. Estrogen receptors present a statistically significant inverse relationship with c-erb B2.

Key words:
Breast cancer
C-erb B2
Prognosis
Immunohistochemistry
El Texto completo está disponible en PDF
Bibliografía
[1.]
Registro de Cáncer de Navarra. Incidencia de Cáncer en Navarra. 1993-1994.
An Sist San Navarra, 22 (1999), pp. 383-392
[2.]
W. Donegan.
Tumor-related prognostic factor for breast cancer.
Cancer J Clin, 47 (1997), pp. 28-51
[3.]
International Breast Cancer Study Group (IBCS). Prognostic importance of occult axilary limph node micrometastases from breast cancer.
Lancet, 335 (1990), pp. 1565-1568
[4.]
F. Johnstone.
Carcinoma of the breast: influence of size of primary lesion and life node involment based on selective biopsy.
Am J Surg, 972 (1972), pp. 158-164
[5.]
O. Kalloniemi, P. Holli, T. Visakorpi, T. Koivula, H. Helin, J. Isola.
Association of c-erb B2 oncogene over-expresion with high rate of cell proliferation, increase risk for visceral metastasis and poor longterm survival in breast cancer.
Int J Cancer, 49 (1991), pp. 650-655
[6.]
A. Borg, B. Baldetorp, M. Ferno, D. Killander, H. Olsson, H. Sigurdsson.
ERB B2 amplification in breast cancer with a high rate of proliferation.
Oncogene, 6 (1991), pp. 137-143
[7.]
R. Elledge, S. Green, D. Ciocca, R. Pugh, D.C. Allred, G.M. Clark, et al.
HER-2 expression and response to tamoxifen in estrogen receptor positive breast cancer: a Southwest Oncology Group Study.
Clin Cancer Res, 4 (1998), pp. 7-12
[8.]
D. Hollywood, H. Hurst.
Targeting gen transcription: a new strategy to down regulate c-erb B2 expression in mamary carcinoma.
Br J Cancer, 71 (1995), pp. 753-757
[9.]
D. Hollywood, H. Hurst.
A novel transcription factor, OB2-1, is reqired for overexpression of the proto-oncogene c-erb B2 in mammary tumour lines.
EMBO J, 12 (1993), pp. 2369-2375
[10.]
D. Slamon, G. Clark, S. Wong, et al.
Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene.
Science, 235 (1987), pp. 177-182
[11.]
U. Lonn, S. Lonn, B. Nilsson, B. Stenkvist.
Prognostic value of erb-B2 and myc amplification in breast cancer imprints.
Cancer, 75 (1995), pp. 2681-2687
[12.]
R. Seshadri, F.A. Firgaira, D.J. Horsfall, K. McCaul, V. Setlur, P. Kitchen.
Clinical significance of HER-2/neu oncogene amplification in primary breast cancer.
J Clin Oncol, 11 (1993), pp. 1936-1942
[13.]
L. Mauriac, G. McGrogan, A. Avril, M. Durand, A. Floquet, M. Debled, et al.
Neoadjuvant chemoterapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS.
Ann Oncol, 10 (1999), pp. 47-52
[14.]
C. Midulla, M. Giovagnoli, C. Valli, A. Vecchione.
Correlation between ploidy status, erb-B2 and p53 immunohistochemical expresion in primary breast carcinoma.
Ann Quant Cytol Histol, 17 (1995), pp. 157-162
[15.]
N. Quenel, J. Wafflart, F. Bonichon.
The prognostic value of c-erb B2 in primary breast carcinomas: a study on 942 cases.
Breast Cancer Res Treat, 35 (1995), pp. 283-291
[16.]
B. Gusterson, R. Gelber, K.P. Goldhirsch, et al.
Prognostic importance of c-erb B2 expression in breast cancer.
J Clin Oncolgy, 10 (1992), pp. 1049-1056
[17.]
L. Hartmann, J. Ingle, L. Wold.
Prognostic value of c-erb B2 overexpression in axillary lymph node postive breast cancer: result from a randomized adjuvant treatment protocol.
Cancer, 74 (1994), pp. 2956-2963
[18.]
B. Tetu, J. Brisson.
Prognostic significance of HER-2/neu oncoprotein expression in node positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy.
Cancer, 1994 (1994), pp. 2359-2365
[19.]
S. Toikkanen, H. Helin, J. Isola, H. Joensuu.
Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30 year followup.
J Clin Oncol, 10 (1992), pp. 1044-1048
[20.]
M. Gallegos, S. González, A. Leon, R. Claure, I. Goñi, L.D. Andrade.
Marcadores tumorales immunohistoquímicos en carcinoma ductal infiltrante de la mama.
Rev Med Chil, 126 (1998), pp. 1216-1223
[21.]
G. Abadjian, R. Antoun.
Carcinomes mammaires: evaluations des recepteurs hormonaux et des marqueurs pS2, erb B2 p-glycoprotein et Ki 67.
J Med Liban, 44 (1996), pp. 10-15
[22.]
C. Carlomagno, F. Perrone, C. Gallo, et al.
c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.
J Clin Oncol, 14 (1996), pp. 2702-2708
[23.]
R. Tiwari, P. Borgen, G. Wong.
HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis.
Anticancer Res, 12 (1992), pp. 419-425
[24.]
U. Lonn, S. Lonn, B. Nilsson, B. Stenkvist.
Prognostic significance of c-erb B2 and int-2 amplification compared with DNA ploidy, S-phase fraction, and conventional clinicopathological features.
Breast Cancer Res Treat, 29 (1994), pp. 237-245
Copyright © 2001. Asociación Española de Cirujanos
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos